 |
Hong KongApril 30, 2026 /PRNewswire/ — Ascletis Pharma Inc. (Hong Kong Stock Exchange Code: 1672, referred to as “Ascletis”) today announced that it will present multiple projects in poster format at the American Diabetes Association (ADA) 2026 Annual Scientific Sessions, to be held from June 5 to 8, 2026, in New Orleans, Louisiana. The presentations include preclinical data on ASC39 (a selective, potent oral small molecule amylin receptor agonist similar to eloralintide for the treatment of obesity), which has been selected as a late-breaking poster.
Presentation Details
Title: ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity
Session: Late Breaking Poster Session (3067-LB)
Date/Time: Sunday, June 7, 2026, 12:30 PM Central Time (CT)
Title: Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity
Session: Sunday General Poster Session (1672-P)
Date/Time: Sunday, June 7, 2026, 12:30 PM Central Time (CT)
Title: ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies
Session: Sunday General Poster Session (1673-P)
Date/Time: Sunday, June 7, 2026, 12:30 PM Central Time (CT)
For more details on the 2026 ADA Scientific Sessions, please visit the ADA conference website (American Diabetes Association).
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class drugs for the treatment of metabolic diseases. Leveraging its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) technology, and Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has independently developed multiple small molecule and peptide drug candidates. These include its core program ASC30, an investigational small molecule GLP-1R agonist for once-daily oral or once-monthly to once-quarterly subcutaneous injection as weight loss therapy and weight maintenance therapy for long-term weight management; ASC36, an amylin receptor agonist peptide; ASC35, a once-monthly subcutaneous GLP-1R/GIPR dual agonist peptide; ASC37, a GLP-1R/GIPR/GCGR triple agonist peptide; ASC39, a selective, potent oral small molecule amylin receptor agonist similar to eloralintide; and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin receptor agonist) for long-term weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
For more information, please visit the website: www.ascletis.com.
For inquiries: